AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Clinical Research | Publishing Language: Chinese | Open Access

Treatment strategies and prognostic factors for relapsed childhood acute lymphoblastic leukemia

You WU, Shu-Hong SHEN, Jing CHEN, Yan-Jing TANG, Cheng-Juan LUO, Zhuo WANG, Chang-Cheng CHEN, Wen-Ting HU( )
Department of Hematology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
Show Author Information

Abstract

Objective

To investigate treatment strategies and prognostic factors in children with relapsed acute lymphoblastic leukemia (ALL).

Methods

A retrospective cohort study enrolled 86 children diagnosed with and relapsed from ALL between 2015 and 2019. Kaplan-Meier method and Cox regression model were applied for analysis.

Results

The median follow-up after relapse was 36 months. The 4-year overall survival (OS) rate was 59%. Multivariate analysis (based on the subgroup receiving induction chemotherapy) identified high-risk relapse and minimal residual disease (MRD) ≥0.01% after induction therapy as independent risk factors for 4-year OS (P<0.05). The introduction of chimeric antigen receptor T-cell (CAR-T) therapy in 2017 significantly improved the 4-year OS rate in children with relapsed ALL (61% vs 26%, P=0.030). According to relapse risk stratification, all low-risk patients survived whether receiving chemotherapy alone or CAR-T therapy. Among intermediate-risk patients, those achieving MRD negativity after re-induction had a high survival rate with chemotherapy (12/13), whereas MRD-positive patients had a high survival rate with CAR-T combined with transplantation (7/8). In high-risk patients, the survival rate for those receiving transplantation (after chemotherapy or CAR-T) was 60% to 62.5%, significantly higher than that of the chemotherapy-alone group (0% survival). The 4-year OS rate for the CAR-T followed by hematopoietic stem cell transplantation group was higher than that of the CAR-T alone group (75% vs 24%, P=0.067).

Conclusions

An individualized treatment strategy based on risk stratification combined with MRD status is recommended for children with relapsed ALL.

References

【1】
【1】
 
 
Chinese Journal of Contemporary Pediatrics
Pages 839-847

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
WU Y, SHEN S-H, CHEN J, et al. Treatment strategies and prognostic factors for relapsed childhood acute lymphoblastic leukemia. Chinese Journal of Contemporary Pediatrics, 2026, 28(7): 839-847. https://doi.org/10.7499/j.issn.1008-8830.2512042

2

Views

0

Downloads

0

Crossref

0

Scopus

0

CSCD

Received: 08 December 2025
Accepted: 12 June 2026
Published: 15 July 2026
© Editorial Office of Chinese Journal of Contemporary Pediatrics.

OA under CC BY-NC-ND 4.0 license